As NASH Space Heats Up, Tobira Strengthens Position With Regado Reverse-Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
New combined company, with $60 million in cash, is hoping to move quickly to fill the unmet medical need of non-alcoholic steatohepatitis. Tobira expects primary endpoint data from a Phase IIb study of cenicriviroc by the second quarter of 2016.
You may also be interested in...
Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making
Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.